The Celonic Group, a Swiss-based Quality Biologics Contract Development and Manufacturing Organization (CDMO) has opened a new Biologics Development Center and Pilot Plant in Basel, Switzerland.
 
This laboratory expansion will help pharmaceutical companies develop and optimize processes using bioprocessing technologies such as Process Intensification and Perfusion. These technologies cut the cost and risks of scaling up the production of biologic medicines, making them more affordable and accessible to more people in the world.
 
As a pioneer in perfusion and intensification processes, Celonic’s “Next Generation” biomanufacturing capabilities support the entire product lifecycle, from the lab bench to market-scale production. The new Biologics Development Center will work seamlessly with Celonic’s GMP manufacturing site in Heidelberg, Germany.
 
Samanta Cimitan, CEO of the Celonic Group, commented: “The cost and complexity of scaling a biologic drug from the lab bench to market-scale production poses a significant barrier to innovation. Celonic’s Biologics Development Center expansion equipped with state-of-the-art ‘Next Generation’ bioprocessing technologies offers capabilities that significantly increase the amount of active ingredient produced, reducing the cost per gram of finished product. We look forward to helping customers, in particular Biotech and Biosimilar companies of all sizes innovate more quickly and improve access to sophisticated medicines.”